|
|
! R6 O. h8 t [# p1 y
Vaccines, 6th Edition
( n: p" }( h% cApply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice./ D% [1 ^2 C3 P6 R0 M# Q
! ?1 ~! { b& |- F: h- zhttp://yun.baidu.com/share/link?shareid=2079860221&uk=3810996606) ?! m! k, I$ P, a
* o$ C* q3 Z& T/ Q, M0 z
SECTION 1: General aspects of vaccination
! |2 j9 _3 k; J$ O$ @: u' s1 A short history of vaccination 1
! z) S1 j/ k' ]$ S& V2 Vaccine immunology 14
' }+ w6 ]; [ v; U5 Y3 The vaccine industry 33
% X2 Q" w7 m/ Y& j; H! K4 Vaccine manufacturing 44
# V; I, H% k4 J5 Evolution of adjuvants across the centuries 58
! @7 n8 q% L' I( H4 ]9 [6 Vaccine additives and manufacturing residuals in the United States:
" n: h$ \8 B; s* |8 u- F: Rlicensed vaccines 71$ _9 u8 ~6 e4 c( \$ M) d7 W
7 Passive immunization 80
1 \5 j0 ^+ N" B' w, b; Y1 y8 General immunization practices 88
2 L: S* y8 ~' G) w: g/ ASECTION 2: Licensed vaccines
0 |1 d3 a& |$ k0 l7 u( E* [* ]9 Adenovirus vaccines 1132 V9 Q1 E: c+ X: e+ \( H
10 Anthrax vaccines 127' E9 y) d: R7 {. i
11 Cholera vaccines 141; D, `2 g+ R$ |* E
12 Diphtheria toxoid 153
7 x1 B* X/ v# E0 s9 z' M13 Haemophilus influenzae vaccines 1675 \( B: T) l" @: F2 B% R7 d( V1 R
14 Hepatitis A vaccines 183# ]0 h: U# [+ h; c, e; ~2 p
15 Hepatitis B vaccines 205
; i) {4 C- l4 @16 Human papillomavirus vaccines 235! |- ^% x6 P$ r0 ?
17 Inactivated influenza vaccines 257
- `; r+ M3 D4 u) w4 D; z( F18 Influenza vaccine-live 294
& h; j D, h0 \; @# S19 Japanese encephalitis vaccines 3126 T: @ P4 u0 P( h1 R
20 Measles vaccines 352
9 ]% s# A, _6 l; I1 R21 Meningococcal vaccines 388
3 ^: r6 ]: k% A4 b. {22 Mumps vaccine 4190 ?$ W* d- V, R8 I/ m3 H; {
23 Pertussis vaccines . 4476 q+ Q2 ~$ X' Y. ~6 S1 x
24 Plague vaccines 4930 n3 `* v9 [: X2 |
25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504
0 c. Z9 L. e. Z4 f3 C+ d26 Pneumococcal polysaccharide vaccines 542
_$ @+ {4 G: ~" I; j27 Poliovirus vaccine-inactivated . 573
4 C6 A+ T' l q+ N28 Poliovirus vaccine-live 598
4 P- Y# F1 ?" G: O1 L0 ]% |29 Rabies vaccines .646- g, w7 X& b: G, g _ H3 [6 u8 x
30 Rotavirus vaccines . 6691 h8 f& d* o7 Q/ Q% P* q1 f
31 Rubella vaccine 688; ~9 M+ _, z d+ `6 t5 p9 q1 x
32 Smallpox and vaccinia 718
7 Z+ R" O" p* Y, G8 Q33 Tetanus toxoid 746
$ @4 |' @. A2 ?34 Tick-borne encephalitis virus vaccines 773
, H/ S6 n# _, j/ B5 }& ~35 Tuberculosis vaccines 789
E- t, l g. J0 q% B: b36 Typhoid fever vaccines 812
P2 n% ]( x2 K( d37 Varicella vaccine 8378 G% B/ D1 k# i8 s
38 Yellow fever vaccine 870
% @5 `0 H; }" p4 j6 m O39 Zoster vaccine 969
d% N# R `4 H+ E& F40 Combination vaccines 981
' V& g, H% m; v P7 X$ p. P; bSECTION 3: Vaccines in development and new vaccine strategies0 h9 w0 _! X3 Z2 P5 c! H; P: g
41 Biodefense and special pathogen vaccines 1008
7 k- S" J) Y! _42 Therapeutic cancer vaccines 10182 X( ^; i% R8 `0 N. ~( K
43 Cytomegalovirus vaccines 1032
* j& C. E+ ]7 X( w% A44 Dengue vaccines 1042+ t7 H' P) w3 c+ O
45 Diarrhea caused by bacteria 1052, L y& n7 T% t ^
46 Ebola vaccine 1060% h! X$ m* H. B) j6 l' o/ J
47 Epstein-Barr virus vaccines 1068
" N( p d4 s# y0 O, b+ |48 Hepatitis C vaccines 1074 N% V/ z4 R5 s
49 Hepatitis E vaccines 1085
9 E$ X, H2 L9 b1 K50 Herpes simplex virus vaccines 10907 E$ f& E) I# A: K
51 Human immunodeficiency virus vaccines 1097
' f5 s$ U) x$ t4 G; j+ l4 C2 A52 Lyme disease vaccines 1122
5 |/ `; y) Y9 @0 S6 z: S4 J: l53 Malaria vaccines 11339 k4 m5 @- R. A* L5 @+ q9 k
54 Noninfectious disease vaccines 11383 H, F \6 D% N: r, O* v$ T4 h
55 Respiratory syncytial virus and parainfluenza virus vaccines 1146
1 n( V7 Y$ s; p# J2 U @* v56 Parasitic disease vaccines 1154: r6 {9 Y. t# T& O* x2 D
57 Staphylococcus aureus vaccines 1161
; o8 t9 C9 f" {+ l, n58 Streptococcus group A vaccines 1169
' I2 C+ R2 |. @+ H59 Streptococcus group B vaccines 1176
7 k. y+ `( D+ T: U6 |! J6 o60 Technologies for making new vaccines 1182! z* U9 h+ Y! @0 k
61 Alternative vaccine delivery methods 1200* h' N5 j4 q# j
62 The development of gene-based vectors for immunization 1232
* l2 z8 F/ v R. M6 w) vSECTION 4: Vaccination of special groups
3 D! u. L6 H! V) D4 T, E63 Vaccination of immunocompromised hosts 1243
+ W. s) v8 A1 A L/ d64 Vaccination of human immunodeficiency virus-infected persons 1257! N' b% e! w3 g. M
65 Vaccines for international travel 12702 M6 C3 L2 M; [' d& F3 H5 {
66 Vaccines for health care personnel 1290# @$ q: k% e# \/ T; f% k! X
SECTION 5: Public health and regulatory issues5 k* t1 X" p9 V+ K# K" G$ q$ W
67 Immunization in the United States 1310
% X# g2 i$ ?: h Z7 n68 Immunization in Europe . 1334% G# G9 R/ Y+ `6 }, l
69 Immunization in the Asia-Pacific region 13533 O3 x* _% u* h5 T$ l
70 Immunization in developing countries 13699 U# i- O8 @" ^3 j3 Q ^9 o. u
71 Community immunity 1395
/ `( a' s5 C3 q72 Economic analyses of vaccine policies 14131 A3 r0 o1 j6 Y# N/ h0 c; B9 y
73 Regulation and testing of vaccines 1427
0 x. n0 H9 A) a T, [0 e74 Regulation of vaccines in Europe 14470 J; W/ e* H- J7 @
75 Regulation of vaccines in developing countries 1454* `1 D ^. B# j& W! |* w
76 Vaccine safety 1464
B! y) Y0 V' a' u" I4 f- ?77 Legal issues . 1481
. Z& V! }, l. {; p' o3 M5 }" @78 Ethics 15081 f K" e% Q, d; I& U m& u' C" ]
$ O8 B! R, i/ X5 P6 P9 G2 e0 ~* z- ^0 i" d% G
}9 \" V/ X* b& U/ ^
" t( h0 v1 g2 m& k; Y. H g
|
|